register

News & Trends - Pharmaceuticals

MA’s growing concern for Australia’s post COVID-19 health hangover

Health Industry Hub | April 22, 2020 |

Pharma News: Medicines Australia welcomes the announcement by Prime Minister the Hon Scott Morrison that elective surgery will “gradually restart” but urges increased concurrent attention on Australia’s chronic health care needs to help reduce a significant post COVID-19 health hangover.

Medicines Australia CEO Elizabeth de Somer said “While elective surgery is extremely important, we have seen a marked drop-off in pathology testing and GP visits as a result of COVID-19. The pathology sector alone has seen a 40% drop in routine pathology testing in recent weeks, meaning over 60,000 Australians every day are not getting the tests they need.”

“Not maintaining the nation’s regular health priorities may have catastrophic consequences – for instance taking backward steps in managing diseases like diabetes, or the difference between a stage two and stage four cancer diagnosis.

Register FREE and join 22,000+ industry professionals receiving the latest industry news and engaging content from Health Industry Hub, the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.

“Hospitals, GPs and pathology centres are well equipped to comply with the rigorous COVID-19 hygiene practices and telehealth measures are actively in place. I strongly urge patients and carers to continue with their regular consultations, tests and care arrangements – so we don’t generate a significant back-log as our social distancing measures are relaxed,” she said.

The decision by the National Cabinet on elective surgery will see restrictions eased on about 25% of activity in elective surgery in private and public hospitals.

The pharmaceutical industry stands ready to support hospitals and healthcare workers as they recommence elective surgeries.

“Pharmaceutical manufacturers have worked with wholesalers, hospitals and the Federal Government to ensure there are supplies of medicines and products needed for surgery as it recommences,” said Ms de Somer.

“This includes increasing the supply of critical care medicines and protective equipment for hospital workers as well as diagnostics and devices like ventilators.

“As an industry we have also been working very closely with patient groups on ways to best communicate the importance of maintaining continuity of care.

“Right now, we need to ensure Australians are as healthy as possible with this challenging backdrop in order to lessen the effects of COVID-19 and to minimise the future long-term health hangover that will impact our hospital and healthcare system potentially slowing down our recovery,” concluded Ms de Somer.

HCP engagement during COVID-19. Fill the gap of reduced field force activities. Health Industry Hub combines expertise in delivering digital health content with high engagement and 20+ years industry experience. Created by industry for industry. Contact us.


News & Trends - Biotechnology

AusBiotech appoints new CEO: Former Sanofi corporate affairs and sustainability leader takes the helm

AusBiotech appoints new CEO: Former Sanofi corporate affairs and sustainability leader takes the helm

Health Industry Hub | April 23, 2024 |

Biotech News: AusBiotech, the nation’s leading industry body for the biotech sector, has named former leader at Sanofi, Rebekah Cassidy, […]

More


News & Trends - MedTech & Diagnostics

Federal government invests in Siemens Healthineers scanner to 'reduce wait times' for cancer diagnosis

Federal government invests in Siemens Healthineers scanner to ‘reduce wait times’ for cancer diagnosis

Health Industry Hub | April 23, 2024 |

MedTech & Diagnostics News: The Albanese Government is investing $12 million through the 2024–25 Budget, to purchase and install a […]

More


News & Trends - MedTech & Diagnostics

Cardiac device benefits face more cuts, while technical services remain secure in the short term

Cardiac device benefits face more cuts, while technical services remain secure in the short term

Health Industry Hub | April 23, 2024 |

MedTech & Diagnostics News: Starting from July 2024, Cardiac Implantable Electronic Devices (CIED) listed on the Prescribed List (PL) will […]

More


News & Trends - Biotechnology

CSL's world-first gene therapy heads for MSAC assessment

CSL’s world-first gene therapy heads for MSAC evaluation

Health Industry Hub | April 23, 2024 |

Biotech News: CSL’s world-first gene therapy for haemophilia B is scheduled for consideration at the upcoming Medical Services Advisory Committee (MSAC) […]

More


This content is copyright protected. Please subscribe to gain access.